Search the Newsreel

Nephros Inc (NEPH) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Nephros Inc (NEPH), listing major individual and institutional holders and their respective proportions. It also provides a breakdown of shareholder types, including hedge funds and individual investors, and tracks institutional shareholding changes over several quarters. Key shareholders …

Smith & Nephew plc (SNN) latest stock news and headlines

This article provides a compilation of recent news and headlines regarding Smith & Nephew plc (SNN), a medical technology company. It highlights product launches, strategic expansions, expert consensus, and analyst and activist investor opinions affecting the stock's performance. The company's stock performance relative to …

NEPH Q1 2026 Earnings: EPS Slightly Below Estimates; Stock Declines 3.45% - EBITDA Estimate Trend

NEPH|Nephros Inc|Price:3.450|Chg%:-0.190

This article provides a comprehensive stock analysis of Nephros Inc (NEPH) based on TradingKey's stock score system. It highlights the company's healthy fundamentals, high growth potential with steady revenue growth, and relatively fair valuation. The analysis also covers institutional ownership, analyst ratings, and a …

Smith+Nephew Expands ASC Platform to Support Value-Based Care

Smith+Nephew SNN recently unveiled an expanded ASC Solutions strategy aimed at helping ambulatory surgery centers ("ASCs") improve operational efficiency, accelerate growth and deliver better patient outcomes. The enhanced enterprise approach combines the company's procedural technologies, data-driven insights and strategic partner network to support ASC …

Smith & Nephew Advances $250 Million Share Buyback, Repurchasing Over 1 Million Shares in Latest Week

Smith & Nephew has announced the repurchase of 1,069,609 ordinary shares between July 17 and 23, 2026, as part of its $250 million share buyback program. The shares were acquired at an average price of 1,127.68 pence per share. Since the program began on …

Smith & Nephew stock trades steady as surgical portfolio supports earnings

Smith & Nephew's stock remains stable due to strong performance in its orthopedics and sports medicine franchises. The company reported increased revenue of $5.5 billion in fiscal 2024, up from $5.2 billion in 2023, and maintained a mid-teens trading margin despite investments in innovation …

What Smith & Nephew (LSE:SN) Says About The Current Blue-Chip Stocks Story

Nephrocare Health Services hosts Q1FY27 earnings call on Aug 12

What Smith & Nephew (LSE:SN) Says About The Current UK Dividend Stocks Story

Smith+Nephew (NYSE: SNN) schedules Q2 and H1 2026 results call

Smith+Nephew (NYSE: SNN) has announced it will release its second quarter trading and first half 2026 results on August 4, 2026, at 7:00 AM BST / 2:00 AM EDT. A conference call for financial analysts will follow at 11:30 AM BST / 6:30 AM …

Smith & Nephew stock trades steady as orthopedics margins recover

Smith & Nephew's stock is reflecting improved profitability, driven by margin gains in its orthopedics and sports medicine segments in 2023. The company saw a 6% revenue growth to $5.5 billion in 2023 and increased adjusted trading profit, indicating effective cost control and a …

Bank of America reports 3.172736% voting stake in Smith & Nephew (NYSE: SNN)

Bank of America Corporation has reported a 3.172736% voting stake in Smith & Nephew (NYSE: SNN) through a TR-1 notification. This holding comprises 2.402237% from shares and 0.770499% from financial instruments, including a Right to Recall and various cash-settled swaps. The total voting rights …

Smith+Nephew introduces expanded enterprise ASC Solutions Strategy to support growth, performance and value-based care

Smith+Nephew has launched an expanded enterprise ASC Solutions Strategy focused on helping ambulatory surgery centers (ASCs) optimize costs, improve quality, and enhance performance. This strategy includes the ASC ONE delivery model, which simplifies ASC development and operations by providing a single point of coordination …

Smith & Nephew stock rises on earnings context and investor focus

Smith & Nephew's stock is gaining attention due to its strong 2025 financial performance, including $5.83 billion in revenue and a 17.9% trading profit margin. The company's underlying revenue growth of 7.6% and efficient conversion of growth into operating leverage are key factors. Investors …

Nephros to Present at Maxim Group’s “Health, Wellness & Longevity” Virtual Summit on July 22, 2026

Nephros, Inc. (Nasdaq: NEPH) CEO Robert Banks is scheduled to present at Maxim Group’s "Health, Wellness & Longevity" virtual summit on July 22, 2026, at 10:00 a.m. ET. The summit will focus on consumer wellness trends, scientific innovations in food and beverages, and strategies …

Smith & Nephew (NYSE: SNN) leaders buy ADS through employee stock plan

Three senior leaders at Smith & Nephew plc (NYSE: SNN), including the CEO, President of Global Operations, and President of Sports Medicine, purchased American Depositary Shares (ADS) through the company's Employee Stock Purchase Plan. The transactions, which occurred on July 10, 2026, involved purchases …

Smith+Nephew's ASC ONE provides one coordination point for surgery centers

Smith+Nephew (NYSE: SNN) has launched ASC Solutions, an expanded enterprise strategy for ambulatory surgery centers (ASCs) aimed at optimizing costs, enhancing quality, and improving outcome performance. This strategy includes expanding its ASC ONE delivery model into an integrated platform that coordinates various aspects of …

Smith & Nephew stock trades steady as surgical device margins support guidance

Smith & Nephew stock shows stable performance, with orthopedic and wound-care margins supporting current guidance. The company relies on its diversified portfolio in orthopedics, sports medicine, and advanced wound management, maintaining focus on organic revenue growth and improving trading profit margins. Investors are watching …

Smith & Nephew stock advances on earnings and margin focus

Smith & Nephew's stock movement is being evaluated based on its latest earnings, margin, and cash flow performance. The company, a global medical technology group, focuses on orthopedics, sports medicine, and wound care. Investors are primarily looking at sales growth, margin development, and free …

Nephros to Participate in the 'Health, Wellness & Longevity” Virtual Conference Presented by Maxim Group LLC on Wednesday, July 22nd at 10:00 a.m. ET

Nephros, Inc. announced that its President and CEO, Robert Banks, will present at the "Health, Wellness & Longevity" virtual conference hosted by Maxim Group LLC on Wednesday, July 22, 2026, at 10:00 a.m. ET. The conference will delve into consumer wellness and scientific innovation, …

Smith & Nephew stock holds steady as 2025 revenue and margin guide frame the next update

Smith & Nephew's stock performance is currently framed by its 2025 financial guidance, which includes an expected underlying revenue growth of 4.0% to 5.0%, a trading profit margin of around 19.5%, and cash conversion of approximately 90%. These figures serve as key benchmarks for …

Nephros added to Russell Microcap Index

Nephros, Inc., a company specializing in water purification and pathogen detection, has been added to the Russell Microcap Index. This inclusion is part of the annual reconstitution of Russell indexes, which is a significant event for institutional investors. The company's CEO expressed enthusiasm for …

Northland initiates Nephros stock coverage with $4 price target

Northland has initiated coverage on Nephros Inc. (NASDAQ:NEPH) with a Market Perform rating and a $4.00 price target. The analyst noted that Nephros, a water filtration company, has successfully shifted its strategy under new management, leading to increased recurring sales and revenue growth. This …

Smith & Nephew stock holds steady as Q1 2026 growth and margin improvement underpin outlook

Smith & Nephew's stock is supported by robust Q1 2026 revenue growth and improving trading profit margins, driven by stronger Orthopaedics demand and disciplined cost control. The company reported increased revenue from $5.5 billion in fiscal 2023 to over $5.8 billion in 2025, with …

Smith & Nephew (SNN) Slips 2.6% as Market Digests Headwinds - Pre-Earnings Momentum

Nephros | 8-K: Current report

This article is a current report filed by Nephros, likely an 8-K form, which is used to announce major events that shareholders should know about. Without further details, the specifics of the event contained within the document are not accessible.

Smith & Nephew stock trades steadily as recent earnings highlight margin focus

Smith & Nephew's recent financial results indicate steady revenue growth but also highlight ongoing margin pressures, driven by cost inflation and R&D investments. The company, which specializes in orthopedics, sports medicine, and advanced wound care, reported approximately $5.5 billion in annual revenue with incremental …

Former Smith+Nephew Global Orthopaedics President Craig Gaffin Joins MedEdge Holdings as Partner

Craig Gaffin, former president of Smith+Nephew's global orthopaedics business, has joined MedEdge Holdings as a partner. MedEdge, founded in 2025, focuses on acquiring, building, and commercializing innovative surgical technology companies and expanding a nationwide commercial infrastructure. Gaffin's extensive commercial leadership experience aims to help …

Smith+Nephew unveils Lynx Coblation Laryngeal Wand for laryngology

Smith+Nephew has launched its Lynx Coblation Laryngeal Wand, a device designed for ENT surgeons performing laryngology procedures. The wand offers flexibility, an extended working length, and malleability, allowing for fine dissection and mass debulking at lower temperatures than traditional lasers. It facilitates radial incisions …

Smith+Nephew introduces groundbreaking LYNX™ COBLATION™ Laryngeal Wand for ENT surgeons

Smith+Nephew has launched its new LYNX™ COBLATION™ Laryngeal Wand, a multi-purpose surgical tool designed specifically for ENT surgeons. This wand offers improved efficiency, better access to target anatomy, and a malleable shaft, leveraging Smith+Nephew’s COBLATION Technology for precise tissue removal at low temperatures. Surgeons …

Smith & Nephew stock holds steady as medical technology portfolio supports long-term growth

Smith & Nephew (GB0009223206) is a global medical technology company focusing on orthopedics, sports medicine, and advanced wound management. Its diversified portfolio, including established implant franchises and minimally invasive technologies, supports long-term growth and stable cash flows. The company's products are sold worldwide to …

Smith & Nephew SNATS, Inc. (SNN): Investor Outlook on a Healthcare Giant with 10.98% Upside Potential

Smith & Nephew SNATS, Inc. (NYSE: SNN) is presented as a compelling investment opportunity in the healthcare sector, offering a 10.98% upside potential based on analyst targets. The company, known for orthopaedics, sports medicine, and advanced wound management, shows robust revenue growth and a …

SNN5772775 Bond Risk Profile

This page provides a risk profile for the Smith & Nephew plc 5.15% 20-MAR-2027 bond (SNN5772775). It offers an overview of the bond's coupon, redemption, and risks, along with a credit risk assessment highlighting security level, inflation protection, and issuer rating. Additionally, it mentions …

Nephros Inc. (NEPH) Q1 2026 Earnings: EPS Misses Estimate by Narrow Margin, Stock Declines - Earnings Power Value

Nephros joins Russell Microcap Index after annual reconstitution